Motawi T.M.K.Zakhary N.I.Salman T.M.Tadros S.A.Biochemistry DepartmentFaculty of PharmacyEgypt; Cancer Biology DepartmentNational Cancer InstituteEgypt; Cairo UniversityEgypt; Al-Azhar UniversityEgypt; MSA UniversityEgypt2020-01-252020-01-25201215137368https://doi.org/10.7314/APJCP.2012.13.11.5399PubMed ID :https://t.ly/EXDV3ScopusAims and Background: Human leukocyte antigen-G and interleukin-2 receptor play pivotal roles in the proliferation of lymphocytes, and thus generation of immune responses. Their overexpression has been evidenced in different malignant hematopoietic diseases. This study aimed to validate serum soluble human leukocyte antigen-G (sHLA-G) and serum soluble interleukin-2 receptor (sIL-2R) as an additional tool for the diagnosis and follow up of acute lymphoblastic leukemia (ALL). Subjects and Methods: Both markers were determined by ELISA in the serum of 33 ALL pediatric patients before treatment and after intensification phase of chemotherapy as well as in the serum of 14 healthy donors that were selected as a control group. Results: ALL patients showed abnormal CBC and high serum lactate dehydrogenase, which were improved after chemotherapy. Also, there was a non-significant increase in serum sHLA-G in ALL patients compared with the control group. However, after chemotherapy, sHLA-G was increased significantly compared with before treatment. On the other hand, serum sIL-2R in ALL patients was increased significantly compared with the control group. After chemotherapy, sIL-2R decreased significantly compared with before treatment. Conclusions: From these results it could be suggested that measurement of serum sHLA-G might be helpful in diagnosis of ALL, while sIL-2R might be useful in diagnosis and follow-up of ALL in pediatric patients.English2 receptorAcute lymphoblastic leukemiaGSoluble human leukocyte antigenSoluble interleukinArticlehttps://doi.org/10.7314/APJCP.2012.13.11.5399PubMed ID :